Zheng Quan Shi Bao·2026-01-06 13:30Group 1 - Baihua Pharmaceutical announced the termination of its control rights change plan due to the lack of consensus among major stakeholders [1][3] - The company's stock was suspended from trading on December 29, 2025, after a significant increase in share price of 6.54% and 5.88% in the two trading days prior to suspension, with a total market value of 4.707 billion yuan [1][3] - For the first three quarters of 2025, Baihua Pharmaceutical reported revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, up 36.41% year-on-year [3] Group 2 - Siwei Liekong also announced the termination of its control rights change plan after failing to reach an agreement on key terms with the transaction counterparties [4][6] - The company's stock was suspended from trading on December 29, 2025, with a stable price trend prior to suspension and a total market value of 10.6 billion yuan [4][6] - Siwei Liekong stated that the termination of the control rights change plan would not have a significant adverse impact on its business performance and financial status [6]